Category Archives: Conferences

Kimberly Jewett Consulting, Inc. Hires Veteran Advocate

Beth Fairchild Brings Years of Experience to Patient Advocacy

SAN ANTONIO, TX – December 8, 2015 – Kimberly Jewett Consulting, Inc., a leader in patient advocacy for life sciences markets, is pleased to announce the addition of Virginia “Beth” Fairchild to their team during the 2015 San Antonio Breast Cancer Symposium.

Beth, a seasoned professional, will hit the ground running as she brings several years worth of hands-on client and management expertise, backed by her personal experience as a metastatic breast cancer survivor and passionate patient advocate. Her qualifications include a successful track record in healthcare marketing and sales, and her extensive experience in specifically, metastatic breast cancer with a comprehensive understanding of this sophisticated arena.

As an associate, Beth will be contributing to the growth of the organization by concentrating on enrichment of client satisfaction. In her new role, Beth will act as a conduit to clients when she designs and implements new strategies, and as a liaison to new opportunity development – translating client needs into viable product enhancements and solutions.

When asked about her new role with KJC, Beth replied, “I joined Kimberly Jewett, Inc. because I wanted to be part of a team actively involved in driving patient needs and public understanding of this disease. One hundred and twenty-three women and men will die today from METAstatic Breast Cancer, and one day I will be one of those 123. I look forward to working Kim and moving forward with the pharmaceutical industry to build pharma/patient relationships and to create support and advocacy programming.”

CEO and Founder, Kimberly Jewett adds, “We are excited, honored, and grateful to have Beth join our team, supporting the needs of our clients. Our passion, combined with our purpose and professional skillset, will truly impact the lives of cancer patients and their families, and we are both blessed to have the opportunity to be that voice. While honoring the patients who are fighting, surviving, and thriving every day of their fight, and remembering the ones who lost their lives way too soon. Together, WE CAN make a difference in the lives of cancer patients and their families. People just like US.”

ASCO Breast Cancer Symposium 2015 News Roundup

MRI improved breast cancer detection in average risk women

Oncology Practice reports that research suggests that “MRI-screening may improve the detection of biologically relevant breast cancer in women who are at average-risk, and reduce the interval-cancer rate down to 0%, at a low false-positive rate.” In the “cohort of heavily pre-screened women at average risk, the additional cancer yield achieved through MRI was high, at 15.8 cases per 1,000 women screened, and the added cancers diagnosed by MRI tended to be of high nuclear grade.” The findings were presented at the 2015 ASCO Breast Cancer Symposium.

Use Of Aromatase Inhibitors In The Adjuvant Setting May Delay Development Of Contralateral Breast Cancer

Oncology Practice reports that research suggests “the use of aromatase inhibitors (AIs) in the adjuvant setting appears to delay the development of contralateral breast cancer.” The “effect was particularly prevalent among breast cancer patients who were BRCA positive.” The research was presented at the 2015 ASCO Breast Cancer Symposium.

Age At Biopsy and Number Of Atypical Hyperplasia Foci May Be Good Predictors Of Risk For Subsequent Breast Cancer

Oncology Practice reports that research suggests that “a woman’s age at biopsy and the number of atypical hyperplasia foci appear to be good predictors of risk for subsequent breast cancer.” The “review of pathology records and medical history on more than 13,000 women with benign breast disease showed that a predictive model including age and atypia effectively identified those women with atypical hyperplasia at highest risk for developing breast cancer.” The findings were presented at the ASCO Breast Cancer Symposium.

Radiotherapy not needed for all women post mastectomy

Oncology Practice reports that research suggests that “postmastectomy radiotherapy should not be routinely recommended for breast cancer patients with microscopic nodal metastases (N1mic) and T1-2 tumors.” Investigators found that “in patients with T1-2, N1 disease who were treated with standard therapies, the study authors found that overall, there were low rates of locoregional failure.” The findings were presented at the 2015 ASCO Breast Cancer Symposium.

Many women with triple-negative breast cancer aren’t screened for BRCA

Oncology Practice reports that research indicates that “many younger women diagnosed with triple-negative breast cancers do not get tested for BRCA, despite guideline recommendations.” Researchers found that “among 173 women with triple-negative tumors – lacking the HER2, estrogen and progesterone receptors –17% of those who should have been tested for BRCA according to National Comprehensive Cancer Network (NCCN) guidelines, were not tested.” The findings were presented at the ASCO Breast Cancer Symposium.

Visit Leica Biosystems at USCAP 2015 To Look Inside Einstein’s Brain

Leica Biosystems, a global leader in automation and workflow solutions for anatomic pathology, is providing participants of the USCAP meeting in Boston, MA, March 21-27, 2015with a rare opportunity to look inside Albert Einstein’s brain.

Leica Biosystems invites attendees to come to the Best Brains in Pathology exhibit at booth #901 to explore over 500 slides of Einstein’s brain and examine the Nobel Prize-winning physicist’s neuroanatomy. The original slides were prepared by Dr. Thomas Harvey, who conducted the autopsy of Albert Einstein in 1955. These slides were scanned using an Aperio digital pathology scanner to capture the vast amount of information contained within the slides at a resolution high enough so that the slides can be stored safely away, while the data can be made available to everyone.

This remarkable collection of slides, in the form of an interactive display, is on loan from the National Museum of Health and Medicine, Chicago. “We are privileged to share such an important artifact as Einstein’s brain at USCAP,” said Puneet Sarin, Leica Biosystems vice president and general manager of its Pathology Imaging Business. “However, this exhibit is not just about preservation. Our visitors will discover innovative Leica Biosystems solutions that support sharing, collaboration, and analysis for healthcare professionals and researchers around the world.”

Participants are encouraged to “Look inside Einstein’s brain” at this year’s meeting, and join with the greatest minds at USCAP to transform pathology together.

About Leica Biosystems 

Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients’ lives. Leica Biosystems provides anatomical pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Leica’s easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries. It has manufacturing facilities in 7 countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Further information can be found at